CO2021014748A2 - Anti-bcma antibody conjugate, compositions comprising it, and methods of making and using the same - Google Patents
Anti-bcma antibody conjugate, compositions comprising it, and methods of making and using the sameInfo
- Publication number
- CO2021014748A2 CO2021014748A2 CONC2021/0014748A CO2021014748A CO2021014748A2 CO 2021014748 A2 CO2021014748 A2 CO 2021014748A2 CO 2021014748 A CO2021014748 A CO 2021014748A CO 2021014748 A2 CO2021014748 A2 CO 2021014748A2
- Authority
- CO
- Colombia
- Prior art keywords
- compositions
- methods
- making
- same
- antibody conjugate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
Conjugados de anticuerpo con especificidad de fijación para BCMA (BCMA) y sus isoformas y homólogos, y composiciones que comprenden los conjugados de anticuerpo, que incluyen composiciones farmacéuticas. También métodos para producir los conjugados de anticuerpo y las composiciones, además de métodos para usar los conjugados de anticuerpo y composiciones, por ejemplo, en métodos de diagnóstico y tratamiento.Antibody conjugates with binding specificity for BCMA (BCMA) and its isoforms and homologues, and compositions comprising the antibody conjugates, including pharmaceutical compositions. Also methods of producing the antibody conjugates and compositions, as well as methods of using the antibody conjugates and compositions, for example, in methods of diagnosis and treatment.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962843226P | 2019-05-03 | 2019-05-03 | |
PCT/US2020/031067 WO2020227110A1 (en) | 2019-05-03 | 2020-05-01 | Anti-bcma antibody conjugate, compositions comprising the same, and methods of making and using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021014748A2 true CO2021014748A2 (en) | 2022-01-17 |
Family
ID=70775576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0014748A CO2021014748A2 (en) | 2019-05-03 | 2021-11-02 | Anti-bcma antibody conjugate, compositions comprising it, and methods of making and using the same |
Country Status (17)
Country | Link |
---|---|
US (1) | US20220323599A1 (en) |
EP (1) | EP3962946A1 (en) |
JP (1) | JP2022531001A (en) |
KR (1) | KR20220005058A (en) |
CN (1) | CN113966344A (en) |
AR (1) | AR118849A1 (en) |
AU (1) | AU2020270407A1 (en) |
CA (1) | CA3134918A1 (en) |
CL (1) | CL2021002838A1 (en) |
CO (1) | CO2021014748A2 (en) |
EA (1) | EA202193040A1 (en) |
IL (1) | IL287809A (en) |
MX (1) | MX2021013391A (en) |
PE (1) | PE20220336A1 (en) |
SG (1) | SG11202112120WA (en) |
TW (1) | TW202108174A (en) |
WO (1) | WO2020227110A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3774901A1 (en) * | 2018-03-26 | 2021-02-17 | Sutro Biopharma, Inc. | Anti-bcma receptor antibodies, compositions comprising anti bcma receptor antibodies and methods of making and using anti-bcma antibodies |
KR20240004659A (en) | 2021-04-30 | 2024-01-11 | 셀진 코포레이션 | Combination therapy using an anti-BCMA antibody-drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI) |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
LU91067I2 (en) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab and its variants and immunochemical derivatives including immotoxins |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
DE69333082T2 (en) | 1992-02-11 | 2004-05-06 | Cell Genesys, Inc., Foster City | OBTAINING HOMOZYGOTEM BY TARGETED GENETIC EVENTS |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
PT2316940E (en) | 2000-12-18 | 2013-10-16 | Dyax Corp | Focused libraries of genetic packages |
CA2561533C (en) | 2004-04-13 | 2015-06-16 | Yvo Graus | Anti-p-selectin antibodies |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
US8431558B2 (en) | 2004-11-01 | 2013-04-30 | The Regents Of The University Of California | Compositions and methods for modification of biomolecules |
MX344415B (en) | 2007-09-14 | 2016-12-15 | Adimab Inc | Rationally designed, synthetic antibody libraries and uses therefor. |
US8519122B2 (en) | 2010-02-12 | 2013-08-27 | The Regents Of The University Of California | Compositions and methods for modification of biomolecules |
EP3604264A1 (en) | 2010-04-27 | 2020-02-05 | SynAffix B.V. | Fused cyclooctyne compounds |
WO2012134925A1 (en) | 2011-03-25 | 2012-10-04 | Life Technologies Corporation | Heterobifunctional esters for use in labeling target molecules |
US20130251783A1 (en) | 2011-09-14 | 2013-09-26 | Universitat Heidelberg | Liposomes containing permeation enhancers for oral drug delivery |
AU2012356894B2 (en) | 2011-12-23 | 2018-01-18 | Innate Pharma | Enzymatic conjugation of polypeptides |
TW201425336A (en) * | 2012-12-07 | 2014-07-01 | Amgen Inc | BCMA antigen binding proteins |
JP2016507523A (en) * | 2013-02-05 | 2016-03-10 | エンクマフ アーゲー | Bispecific antibodies against CD3ε and BCMA |
US10144782B2 (en) * | 2014-04-30 | 2018-12-04 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Humanized antibodies against CD269 (BCMA) |
EP3218409A2 (en) | 2014-11-11 | 2017-09-20 | Sutro Biopharma, Inc. | Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies |
EP3023437A1 (en) * | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
ES2814550T3 (en) * | 2015-08-17 | 2021-03-29 | Janssen Pharmaceutica Nv | Anti-BCMA antibodies, bispecific antigen-binding molecules that bind BCMA and CD3, and uses thereof |
EP3407917A1 (en) | 2016-01-27 | 2018-12-05 | Sutro Biopharma, Inc. | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates |
WO2018156785A1 (en) | 2017-02-22 | 2018-08-30 | Sutro Biopharma, Inc. | Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same |
MA51447A (en) * | 2017-08-01 | 2020-06-10 | Medimmune Llc | MONOCLONAL ANTIBODY-DRUG CONJUGATE AGAINST BCMA |
RU2020111503A (en) * | 2017-09-18 | 2021-10-20 | Сутро Биофарма, Инк. | ANTIBODY CONJUGATES TO THE ALPHA FOLIC ACID RECEPTOR AND THEIR APPLICATION |
CN109265550B (en) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | BCMA antibodies, chimeric antigen receptors and drugs |
-
2020
- 2020-05-01 CN CN202080033503.2A patent/CN113966344A/en active Pending
- 2020-05-01 PE PE2021001832A patent/PE20220336A1/en unknown
- 2020-05-01 MX MX2021013391A patent/MX2021013391A/en unknown
- 2020-05-01 EP EP20727095.0A patent/EP3962946A1/en active Pending
- 2020-05-01 CA CA3134918A patent/CA3134918A1/en active Pending
- 2020-05-01 SG SG11202112120WA patent/SG11202112120WA/en unknown
- 2020-05-01 AU AU2020270407A patent/AU2020270407A1/en not_active Abandoned
- 2020-05-01 JP JP2021565053A patent/JP2022531001A/en active Pending
- 2020-05-01 EA EA202193040A patent/EA202193040A1/en unknown
- 2020-05-01 US US17/608,097 patent/US20220323599A1/en active Pending
- 2020-05-01 KR KR1020217039171A patent/KR20220005058A/en unknown
- 2020-05-01 WO PCT/US2020/031067 patent/WO2020227110A1/en active Application Filing
- 2020-05-04 TW TW109114833A patent/TW202108174A/en unknown
- 2020-05-04 AR ARP200101258A patent/AR118849A1/en unknown
-
2021
- 2021-10-28 CL CL2021002838A patent/CL2021002838A1/en unknown
- 2021-11-02 CO CONC2021/0014748A patent/CO2021014748A2/en unknown
- 2021-11-02 IL IL287809A patent/IL287809A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20220005058A (en) | 2022-01-12 |
PE20220336A1 (en) | 2022-03-14 |
EP3962946A1 (en) | 2022-03-09 |
WO2020227110A1 (en) | 2020-11-12 |
CL2021002838A1 (en) | 2022-05-27 |
CN113966344A (en) | 2022-01-21 |
JP2022531001A (en) | 2022-07-05 |
EA202193040A1 (en) | 2022-03-25 |
SG11202112120WA (en) | 2021-11-29 |
TW202108174A (en) | 2021-03-01 |
IL287809A (en) | 2022-01-01 |
CA3134918A1 (en) | 2020-11-12 |
AR118849A1 (en) | 2021-11-03 |
MX2021013391A (en) | 2022-01-26 |
AU2020270407A1 (en) | 2021-12-02 |
US20220323599A1 (en) | 2022-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020010303A2 (en) | Conjugates of il-15, and their uses | |
CO2020001823A2 (en) | Cytokine conjugates for the treatment of autoimmune diseases | |
CL2019001740A1 (en) | Novel conjugate of amanitin. | |
CL2022003788A1 (en) | Binding molecules against bcma and uses thereof | |
DOP2020000021A (en) | ANTI-CD39 ANTIBODIES, COMPOSITIONS INCLUDING ANTI-CD39 ANTIBODIES, AND METHODS OF USE OF ANTI-CD39 ANTIBODIES | |
CL2018003758A1 (en) | Anti-dll3-antibody antibody conjugates and methods of use. (divisional application 201800458) | |
BR112018068461A2 (en) | conjugate, pharmaceutical composition, methods for preparing a conjugate and for alleviating a symptom of a cancer. | |
ECSP109878A (en) | ANTI-CD79B ANTIBODIES AND IMMUNOCATE PLAYERS AND METHODS OF USE OF THE SAME | |
CL2023002204A1 (en) | gpcr receptor agonists, pharmaceutical compositions comprising them and methods for their use | |
DOP2010000304A (en) | COMPOSITIONS AND METHODS OF PREPARATION AND USE OF THE SAME | |
MX2020003608A (en) | Compositions and methods for ttr gene editing and treating attr amyloidosis. | |
AR066042A1 (en) | MOLECULES AND METHODS TO MODULATE PROTEIN CONVERTASA-SUBTILISIN / QUEXIN TYPE 9 (PCSK9) | |
CO2021014748A2 (en) | Anti-bcma antibody conjugate, compositions comprising it, and methods of making and using the same | |
BR112017025711A2 (en) | "compositions, process for preparing polyether modified siloxanes and use of innovative compositions" | |
BR112019012796A2 (en) | antineuropillin antigen binding proteins and methods of use thereof | |
BR112021012667A2 (en) | Anti-pd-1 binding proteins and methods of using them | |
CO2022001210A2 (en) | Il-2 conjugates and methods of use to treat autoimmune diseases | |
CY1123396T1 (en) | COMBINATION TREATMENTS INCLUDING IMIDAZOPYRASINONES FOR THE TREATMENT OF PSYCHIATRIC AND/OR COGNITIVE DISORDERS | |
CO2021004789A2 (en) | Pyridazinones and their methods of use | |
BR112018000909A2 (en) | il22 immunoconjugates | |
BR112021025720A2 (en) | Antitissue factor antibody-drug conjugates and related methods | |
BR112019010128A2 (en) | anti-gitr antigen binding proteins and methods of use thereof | |
BR112022008756A2 (en) | ANTI-MESOTHELIN ERIBULIN ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | |
MX2021015846A (en) | Anthracycline derivatives. | |
MX2020004178A (en) | Cannabidiol and chitosan compositions and methods of using the same. |